Teva Launches New Generic Contraceptive in the U.S. Market
Vigodman Out as Teva CEO; Peterburg in on Interim Basis
Teva Confirms Generic Victoza Patent Challenge in the United States
Teva Secures European Approval of Trisenox for Acute Leukemia
Teva secures European approval of Trisenox for first line treatment of low to intermediate risk acute promyelocytic leukemia (APL). Teva Pharmaceutical Industries Ltd. announced it has obtained approval from the European Commission for an indication extension of Trisenox (arsenic trioxide). This marks an important advancement in treatment for acute promyelocytic leukemia (APL) patients in Europe, as it…
